01—Abstract
Summary
Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. reported a total revenue of $563.9 milliona for the year ended December 31, 2023, a 25% increase year-over-year, driven primarily by a 31% rise in precision oncology testing revenue.
Despite this top-line growth, the company continued to incur significant net losses, amounting to $479.4 millionb for the year. The company has a substantial cash and cash equivalents balance of $1.1 billion as of December 31, 2023, which it believes is sufficient to fund its operations for more than 12 months. The company is focused on expanding its product portfolio and market adoption, particularly with its Shield test for early cancer detection, for which a PMA was submitted to the FDA.
However, significant risks remain, including the company's ongoing unprofitability, dependence on third-party payer coverage and reimbursement, and intense competition in the precision oncology market. A recent jury verdict in a patent infringement case resulted in an $83.4 millionc liability accrual, which is a significant concern for investors.
02—Key points
Key Highlights
- Total revenue increased by 25% to $563.9 million in 2023, driven by strong growth in precision oncology testing.
- Precision oncology testing revenue grew by 31% year-over-year, indicating increasing adoption of the company's diagnostic solutions.
- The company continues to operate at a net loss, reporting a loss of $479.4 million for the year ended December 31, 2023.
- Guardant Health maintained a strong liquidity position with $1.1 billion in cash and cash equivalents as of December 31, 2023, providing over 12 months of operational runway.
- The Shield test for early cancer detection has shown promising results, with a PMA submitted to the FDA, and the company is also expanding into lung cancer screening.
- Significant litigation risk exists, with an $83.4 million liability accrued due to a patent infringement jury verdict, which the company is contesting.
- The company faces ongoing challenges related to payer coverage, reimbursement, and intense competition within the precision oncology market.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2023, Guardant Health, Inc. lost $0.85.
- Revenue$563.9M100.0%
- Cost of revenue−$227.1M40.3%
- Gross profit$336.9M59.7%
- Operating costs−$901.6M159.9%
- Operating income−$564.7M100.1%
- Interest, other & tax$85.3M15.1%
- Net income−$479.4M85.0%
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 22, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $563.95M$449.54M | +25.5% |
| Cost of Revenue | $227.05M— | — |
| Gross Profit | $336.90M— | — |
| R&D Expenses | $367.19M$373.81M | −1.8% |
| Operating Expenses | $1.13B$993.92M | +13.6% |
| Operating Income | -$564.73M-$544.38M | −3.7% |
| Interest Expense | $2.58M$2.58M | 0.0% |
| Net Income | -$479.40M-$654.59M | +26.8% |
| EPS (Basic) | $-4.28$-6.41 | +33.2% |
| EPS (Diluted) | $-4.28$-6.41 | +33.2% |
| Shares Outstanding (Basic) | 111.99M102.18M | +9.6% |
| Shares Outstanding (Diluted) | 111.99M102.18M | +9.6% |
05—Questions
Frequently Asked Questions
What is Guardant Health's financial performance in 2023?
In 2023, Guardant Health reported total revenue of $563.9 million, an increase of 25% compared to 2022, driven primarily by growth in precision oncology testing. However, the company incurred a net loss of $479.4 million.
What are the key growth drivers for Guardant Health?
The primary growth driver is the increasing adoption of its precision oncology tests, particularly Guardant360, by both clinical customers and biopharmaceutical companies. The company is also investing heavily in new product development, such as the Shield test for early cancer detection, and expanding its international presence.
What are the major risks facing Guardant Health?
Key risks include the company's ongoing net losses and path to profitability, reliance on third-party payer coverage and reimbursement rates, intense competition in the diagnostics market, potential regulatory changes, and significant legal risks, such as the recently accrued $83.4 million liability from a patent infringement verdict.
How is the company managing its liquidity and capital resources?
Guardant Health ended 2023 with $1.1 billion in cash and cash equivalents, which it believes is sufficient to fund operations for over 12 months. The company has also raised capital through equity offerings in 2023. It continues to monitor its liquidity and may seek additional capital if needed.
06—Continue